Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05314374 · ClinicalTrials.gov registry record · Phase 1
Effect of Bile Acids on Satiety, Cell Function and Body Weight in Patients With Obesity and Abnormal Satiety Phenotype
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT05314374: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT05314374 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05314374, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this research is to study the effect of the study drug (a conjugated bile acid dietary supplement) or placebo on cell function, hormones and body weight.
Interventions
- DRUG Placebo
- DIETARY_SUPPLEMENT Ileocolonic-release conjugated bile acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2023-05-12 |
| Est. Completion | 2024-11-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05314374
The ClinicalTrials.gov registry entry for NCT05314374 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05314374 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05314374 about?
NCT05314374 is a clinical study titled "Effect of Bile Acids on Satiety, Cell Function and Body Weight in Patients With Obesity and Abnormal Satiety Phenotype". The purpose of this research is to study the effect of the study drug (a conjugated bile acid dietary supplement) or placebo on cell function, hormones and body weight.
What is the current status of trial NCT05314374?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2023-05-12. Estimated completion is 2024-11-13.
What interventions are being tested in trial NCT05314374?
The interventions under investigation include: Placebo (DRUG), Ileocolonic-release conjugated bile acid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05314374?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.